Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT201008084536N1
IRCT201008084536N1
Completed
未知

Study for Safety , immunogenicity and efficacy of intramuscular administration of Haemophilus Influenzae type b conjugate vaccine manufactured by Masoondarou Co. (MAS-HibVAC®) in 50 children and compare with foreign sample

Masoondarou Co.0 sites50 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsChildren Haemophilus Meningitis.Meningitis due to Haemophilus influenzae

Overview

Phase
未知
Intervention
Not specified
Conditions
Children Haemophilus Meningitis.
Sponsor
Masoondarou Co.
Enrollment
50
Status
Completed
Last Updated
8 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Masoondarou Co.

Eligibility Criteria

Inclusion Criteria

  • •Inclusion Criteria :
  • •1\-Male or females age 2\-4 months.
  • •2\- Generally in good Health .
  • •3\- Written informed consent by the legal guardians.
  • •4\- No Known immunological deficiency, including HIV infection .
  • •5\- No known serious diseases, including diabetes , and epilepsy .
  • •6\- No involvement in other drug or vaccine clinical trials during the study period .
  • •7\- No current or foreseeable use of immunosupressors within 1 month prior to vaccination and during the period of study .
  • •8\- No known allergy to biological products .
  • •9\- No history of vaccination against Haemophilus Influenzae type b .

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
A Comparative Phase III Clinical Study of Bharat Biotech International Limited Rabies Vaccine INDIRAB reconstituted with 1mL diluent Vs Reference Vaccine, administered Intramuscularly in healthy volunteers as Pre-Exposure treatment.
CTRI/2010/091/000214Bharat Biotech International Limited,Genome Valley, Shameerpet,Ranga Reddy (Distict),Hyderabad-500 078.60
Recruiting
Phase 3
Clinical Trial of quadrivalent Papilloguard4 vaccine (Human Papillomavirus Types 6, 11, 16, 18) manufactured by Nivad Pharmed Salamat in comparison with GardasilGenital wart prevention.Anogenital (venereal) wartsA63.0
IRCT20240120060741N1ivad Pharmed Salamat670
Not yet recruiting
Phase 1
Safety, preliminary efficacy and immunogenicity of traditional Chinese medicine miRNA hydrogel in the treatment of eczema: a randomized, double-blind, placebo-controlled, dose-increasing clinical studyeczema
ITMCTR2000003604Shanghai Skin Disease Hospital
Completed
Phase 1
Investigating of the Immunogenicity and Safety of Lactococcus Lactis Vaccine Related to Human Papillomavirus Type 16
IRCT20190504043464N1Iran University of Medical Sciences200
Completed
Phase 1
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 2-4-6 months.Prophylaxis against infections diseases: Diphtheria, Tetanus, B. pertussis, H. influenzae type b and hepatitis B.
RPCEC00000103Center for Genetic Engineering and Biotechnology (CIGB).624